Ginkgo Bioworks Holdings, Inc. $DNA Shares Acquired by Invesco Ltd.

Invesco Ltd. grew its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 252.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,684 shares of the company’s stock after buying an additional 67,130 shares during the quarter. Invesco Ltd. owned 0.16% of Ginkgo Bioworks worth $534,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Barclays PLC grew its stake in shares of Ginkgo Bioworks by 353.6% in the fourth quarter. Barclays PLC now owns 54,166 shares of the company’s stock valued at $531,000 after buying an additional 42,224 shares in the last quarter. Forbes J M & Co. LLP grew its stake in Ginkgo Bioworks by 56.0% during the 1st quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company’s stock worth $6,239,000 after purchasing an additional 392,832 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Ginkgo Bioworks by 15.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company’s stock worth $412,000 after purchasing an additional 5,746 shares in the last quarter. Northern Trust Corp grew its stake in Ginkgo Bioworks by 11.5% during the 4th quarter. Northern Trust Corp now owns 94,876 shares of the company’s stock worth $932,000 after purchasing an additional 9,791 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Ginkgo Bioworks by 14.4% during the 1st quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company’s stock worth $150,000 after purchasing an additional 3,331 shares in the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.

Ginkgo Bioworks Price Performance

Shares of NYSE DNA opened at $11.12 on Friday. The company has a market capitalization of $658.01 million, a price-to-earnings ratio of -1.90 and a beta of 1.50. The business has a 50-day moving average of $12.16 and a two-hundred day moving average of $9.28. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.00 and a 1 year high of $16.85.

Ginkgo Bioworks (NYSE:DNA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.44) by $0.34. The company had revenue of $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%. Ginkgo Bioworks has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNA has been the subject of several analyst reports. Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a research note on Friday, August 8th. Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research note on Saturday, August 30th. Finally, BTIG Research boosted their target price on Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a research note on Monday, August 25th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.50.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.